The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of JAK2 allele burden on MF outcome in the era of ruxolitinib.
 
Julie Braish
No Relationships to Disclose
 
Prithviraj Bose
Honoraria - Abbvie; Blueprint Medicines; BMS; Cogent Biosciences; CTI BioPharma Corp; GlaxoSmithKline; Incyte; Ionis Pharmaceuticals; Jubilant Therapeutics; Karyopharm Therapeutics; Morphic Therapeutic; MorphoSys; Novartis; Pharmaessentia
Consulting or Advisory Role - Ono Pharmaceutical; Sierra Oncology
Research Funding - Blueprint Medicines (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Cogent Biosciences (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Geron (Inst); Incyte (Inst); Ionis Pharmaceuticals (Inst); Janssen (Inst); Kartos Therapeutics (Inst); Karyopharm Therapeutics (Inst); MorphoSys (Inst); Telios (Inst)
 
Naveen Pemmaraju
Employment - MD Anderson Cancer Center
Leadership - ASCO; ASH
Consulting or Advisory Role - Abbvie; Aplastic Anemia and MDS International Foundation; Aptitude Health; Astellas Pharma; Blueprint Medicines; Bristol Myers Squibb; CancerNet; CareDx; Celgene; Cimeio Therapeutics; Clearview Healthcare Partners; CTI BioPharma Corp; Curio Science; Dava Oncology; EUSA Pharma; Harborside Press; Imedex; Immunogen; Intellisphere; Intellisphere; Magdalen Medical Publishing; Medscape; Menarini Group; Neopharm; Novartis; OncLive; Pacylex; Patient Power; Peerview; Pharmaessentia; Physicans' Education Resource
Research Funding - US DOD (Inst)
Other Relationship - Karger Publishers
(OPTIONAL) Uncompensated Relationships - Dan's House of Hope; Oncology Times
 
Sherry Pierce
No Relationships to Disclose
 
Koji Sasaki
Honoraria - Amgen; Chugai Pharma; Otsuka
Consulting or Advisory Role - Novartis; Pfizer; Takeda
Research Funding - Novartis
Travel, Accommodations, Expenses - Otsuka
 
Zeev Estrov
No Relationships to Disclose
 
Keyur P. Patel
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Syros Pharmaceuticals
 
Hagop M. Kantarjian
Honoraria - Abbvie; Amgen; Ascentage Pharma Group; Astellas Pharma; AstraZeneca/MedImmune; Daiichih-Sankyo (Inst); Immunogen (Inst); Ipsen; Jazz Pharmaceuticals (Inst); KAHR Medical; Novartis; Pfizer; Precision Biosciences; Shenzhen Target Rx; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie
Research Funding - Abbvie (Inst); Amgen (Inst); Ascentage Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Lilly (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst)
 
Lucia Masarova
(OPTIONAL) Uncompensated Relationships - MorphoSys